Abstract
Efflux pumps are considered being mechanisms behind drug resistance in acute myeloid leukaemia (AML). A recently described efflux pump, breast cancer resistance protein (BCRP), can be expressed in AML, but its clinical importance is uncertain. In this study BCRP mRNA expression was determined in samples from 40 AML patients by real-time RT-PCR. The expression varied from negative to 76 times that of control cells. There was no difference in BCRP mRNA expression between patients responding to induction treatment and non-responders. However, in the group of responders, the 14 patients with the highest expression had significantly shorter overall survival (mean 38 months, SEM 15 months) than the 14 patients with the lowest (74 months, SEM 16 months) (P = 0.047). This suggests a possible role of BCRP in drug resistance in AML.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
ATP Binding Cassette Transporter, Subfamily G, Member 2
-
ATP-Binding Cassette Transporters / genetics*
-
ATP-Binding Cassette Transporters / metabolism
-
Adult
-
Aged
-
Cell Line, Tumor
-
Drug Resistance, Neoplasm / physiology
-
Female
-
Gene Expression Regulation, Leukemic
-
Humans
-
Leukemia, Myeloid, Acute / blood
-
Leukemia, Myeloid, Acute / diagnosis
-
Leukemia, Myeloid, Acute / genetics*
-
Male
-
Middle Aged
-
Neoplasm Proteins / genetics*
-
Neoplasm Proteins / metabolism
-
Predictive Value of Tests
-
Prognosis
-
RNA, Messenger / genetics*
-
RNA, Messenger / metabolism
-
Reverse Transcriptase Polymerase Chain Reaction
-
Survival Analysis
-
Treatment Outcome
Substances
-
ABCG2 protein, human
-
ATP Binding Cassette Transporter, Subfamily G, Member 2
-
ATP-Binding Cassette Transporters
-
Neoplasm Proteins
-
RNA, Messenger